Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about $3 billion, as per pharma acquisition news. Based in California, Audentes Therapeutics calls itself a clinical-stage company focused on developing a portfolio of Adeno-associated virus (AAV)-based genetic medicines for the […]
Reblozyl FDA approval : Celgene and Acceleron Pharma have bagged approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) for the treatment of anemia associated with beta thalassemia in adults who need regular red blood cell (RBC) transfusions. Reblozyl is now the first and only erythroid maturation agent to be approved by […]
Alexion acquisition of Achillion : Alexion Pharmaceuticals has agreed to acquire rival US pharma company Achillion Pharmaceuticals for about $930 million in an all-cash deal as per the latest pharma acquisition news. Achillion is a clinical-stage biopharma company, which is engaged in developing oral small molecule Factor D inhibitors for the treatment of people with […]
Pfizer acquisition of Therachon : US pharma giant Pfizer has completed its previously announced acquisition of Swiss biotech company Therachon, which is focused on rare diseases, in a deal worth up to $810 million, as per the latest pharma acquisition news. The clinical-stage Therachon is currently engaged in developing treatment of achondroplasia and short bowel […]
In a significant move within the biotech sector, Biogen, the US-based biotechnology giant, has announced its agreement to acquire Nightstar Therapeutics, a UK-based clinical-stage gene therapy company, in a deal valued at $800 million. The acquisition underscores Biogen’s commitment to expanding its pipeline, particularly in the ophthalmology space, where it aims to address rare and […]
X4 Pharmaceuticals has finalised its merger with Arsanis, creating a late-stage biopharmaceutical company focused on tackling rare diseases and cancer. This strategic move unites two Massachusetts-based companies, with X4 Pharmaceuticals specializing in immune cell trafficking therapies for conditions such as primary immunodeficiencies and cancer, and Arsanis leading the charge in monoclonal antibody (mAb) immunotherapies for […]
Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of idiopathic multicentric Castleman’s disease (iMCD), from Janssen Sciences Ireland in an all-cash deal valued at $115 million. The agreement, which was initially signed in July 2018, marks a significant step for Eusa Pharma as it expands its […]
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for a staggering $62 billion. This acquisition marks a major step in Takeda’s ongoing transformation into a global powerhouse in biopharmaceuticals, with an expanded footprint and a deeper focus on rare […]
Millendo Therapeutics has finalized its merger with OvaScience, a Massachusetts-based biotech firm specializing in female infertility treatments. The transaction, initially announced in August 2018, concludes with Millendo receiving a total of $85.4 million. This sum comprises $35.9 million in cash from OvaScience and an additional $49.5 million from a related financing effort. The merger’s completion […]
In a significant move within the pharmaceutical industry, Alexion Pharmaceuticals, a leading global biopharma company, has announced its acquisition of Syntimmune, a Boston-based clinical-stage biotech firm. The deal, valued at approximately $1.2 billion, marks a strategic expansion for Alexion as it looks to bolster its portfolio of treatments for rare diseases. Under the terms of […]